Clinical Trials
4 trialsNCT01810016 2022-10-12
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Ludwig Institute for Cancer Research
Phase 1 Terminated
NCT02423863 2020-12-17
Poly-ICLC
Oncovir, Inc.
Phase 2 Completed
NCT01079741 2018-02-13
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT02661100 2016-12-07
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
Case Comprehensive Cancer Center
Phase 1/2 Withdrawn